Entries by Uta Mommert

Innate immunity merger raises €75m

Forbion has spearheaded a €75m Series A financing in Norwegian biotech Calluna Pharma. The clinical-stage company resulted from the merger of Oxitope Pharma and Arxx Therapeutics.

Roche jumps ship on AC Immune

<span style="mso-ansi-language:EN-GB" lang="EN-GB">Genentech, Roche’s US subsidiary, is ending its decades-long collaboration with <link https://www.acimmune.com _blank>AC Immune SA</link> after disappointing study results. It has handed the global rights to Crenezumab and […]

MS: Polpharma joins forces with Sandoz

Polpharma Biologics SA has partnered up with Novartis subsidiary Sandoz AG to market a natalizumab biosimilar. As part of the global commercialization agreement, Polpharma Biologics will be responsible for the […]

PharmaMar moves ahead with NDA for Zepsyre

The FDA has given the go-ahead to PharmaMar’s proposal to file for accelerated approval its New Drug Application (NDA) for lurbinectedin monotherapy for the treatment of second-line small-cell lung cancer.

Billions for the circular economy

Together with the EIB, five of the EU’s largest national promotional banks and institutions plan to invest €10bn to accelerate the transition to a sustainable and circular economy.

US$5bn deal for Galapagos

Belgian biotech Galapagos NV has entered into a R&D collaboration with Gilead Sciences. The US drug maker is paying up to US$5bn for Galapagos’ pipeline and drug discovery platform.